Kuros Biosciences Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Kuros Biosciences

Dividende od Kuros Biosciences su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Kuros Biosciences tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Kuros Biosciences su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Kuros Biosciences mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Kuros Biosciences Aktienanalyse

Шта ради Kuros Biosciences?

Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Kuros Biosciences akciji

Kolika je dividenda koju isplaćuje Kuros Biosciences?

U poslednjih 12 meseci, Kuros Biosciences je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Kuros Biosciences će verovatno isplatiti dividendu od 0 CHF.

Kolika je dividendna prinosa za Kuros Biosciences?

Dividendski prinos od Kuros Biosciences trenutno iznosi .

Kada Kuros Biosciences isplaćuje dividendu?

Kuros Biosciences isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Kuros Biosciences?

Kuros Biosciences je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Kuros Biosciences?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 CHF. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Kuros Biosciences?

Kuros Biosciences se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Kuros Biosciences od 17. 11. 2024. u iznosu od 0 CHF, morali ste da imate akciju u depou pre Ex-dana 17. 11. 2024..

Kada je Kuros Biosciences poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 17. 11. 2024..

Kolika je bila dividenda od Kuros Biosciences u godini 2023?

U godini 2023 kompanija Kuros Biosciences je isplatila 0 CHF kao dividende.

U kojoj valuti Kuros Biosciences isplaćuje dividendu?

Dividende od Kuros Biosciences se isplaćuju u CHF.